PURETECH HEALTH PLC - ADR (PRTC) Fundamental Analysis & Valuation

NASDAQ:PRTC • US7462371060

Current stock price

16.01 USD
-0.4 (-2.44%)
Last:

This PRTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. PRTC Profitability Analysis

1.1 Basic Checks

  • In the past year PRTC has reported negative net income.
  • In the past year PRTC has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PRTC reported negative net income in multiple years.
  • PRTC had a negative operating cash flow in each of the past 5 years.
PRTC Yearly Net Income VS EBIT VS OCF VS FCFPRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • The Return On Assets of PRTC (9.16%) is better than 93.05% of its industry peers.
  • PRTC's Return On Equity of 13.48% is amongst the best of the industry. PRTC outperforms 94.02% of its industry peers.
Industry RankSector Rank
ROA 9.16%
ROE 13.48%
ROIC N/A
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
PRTC Yearly ROA, ROE, ROICPRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • PRTC's Profit Margin of 792.96% is amongst the best of the industry. PRTC outperforms 99.42% of its industry peers.
  • In the last couple of years the Profit Margin of PRTC has declined.
  • PRTC does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 792.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
PRTC Yearly Profit, Operating, Gross MarginsPRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PRTC Health Analysis

2.1 Basic Checks

  • PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PRTC has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PRTC has less shares outstanding
  • Compared to 1 year ago, PRTC has a worse debt to assets ratio.
PRTC Yearly Shares OutstandingPRTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRTC Yearly Total Debt VS Total AssetsPRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.62, we must say that PRTC is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of PRTC (1.62) is better than 64.67% of its industry peers.
  • PRTC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • PRTC has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.62
ROIC/WACCN/A
WACC8.58%
PRTC Yearly LT Debt VS Equity VS FCFPRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • PRTC has a Current Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
  • PRTC has a Current ratio of 8.49. This is in the better half of the industry: PRTC outperforms 74.71% of its industry peers.
  • A Quick Ratio of 8.49 indicates that PRTC has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 74.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.49
Quick Ratio 8.49
PRTC Yearly Current Assets VS Current LiabilitesPRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. PRTC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 168.34% over the past year.
  • Measured over the past years, PRTC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -32.49% on average per year.
  • Looking at the last year, PRTC shows a very strong growth in Revenue. The Revenue has grown by 1265.60%.
  • Measured over the past years, PRTC shows a very negative growth in Revenue. The Revenue has been decreasing by -13.22% on average per year.
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%

3.2 Future

  • Based on estimates for the next years, PRTC will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.77% on average per year.
  • Based on estimates for the next years, PRTC will show a very strong growth in Revenue. The Revenue will grow by 223.14% on average per year.
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PRTC Yearly Revenue VS EstimatesPRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2029 2030 500M 1B 1.5B
PRTC Yearly EPS VS EstimatesPRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRTC Valuation Analysis

4.1 Price/Earnings Ratio

  • PRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTC Price Earnings VS Forward Price EarningsPRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTC Per share dataPRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as PRTC's earnings are expected to decrease with -17.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRTC Dividend Analysis

5.1 Amount

  • No dividends for PRTC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRTC Fundamentals: All Metrics, Ratios and Statistics

PURETECH HEALTH PLC - ADR

NASDAQ:PRTC (3/19/2026, 3:16:55 PM)

16.01

-0.4 (-2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-28
Inst Owners69.92%
Inst Owner Change-99.33%
Ins Owners4.72%
Ins Owner ChangeN/A
Market Cap386.94M
Revenue(TTM)6.39M
Net Income(TTM)50.68M
Analysts84
Price Target70.07 (337.66%)
Short Float %0.02%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.4%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.54
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-4.27
EYN/A
EPS(NY)-6.52
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.26
BVpS15.56
TBVpS15.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 9.16%
ROE 13.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 792.96%
GM N/A
FCFM N/A
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.49
Quick Ratio 8.49
Altman-Z 1.62
F-Score7
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)9.91%
Cap/Depr(5y)37.78%
Cap/Sales(3y)7.17%
Cap/Sales(5y)20.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
EBIT growth 1Y13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.57%
EBIT Next 3Y-5.38%
EBIT Next 5Y3.12%
FCF growth 1Y36.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.98%
OCF growth 3YN/A
OCF growth 5YN/A

PURETECH HEALTH PLC - ADR / PRTC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PURETECH HEALTH PLC - ADR?

ChartMill assigns a fundamental rating of 3 / 10 to PRTC.


Can you provide the valuation status for PURETECH HEALTH PLC - ADR?

ChartMill assigns a valuation rating of 0 / 10 to PURETECH HEALTH PLC - ADR (PRTC). This can be considered as Overvalued.


Can you provide the profitability details for PURETECH HEALTH PLC - ADR?

PURETECH HEALTH PLC - ADR (PRTC) has a profitability rating of 3 / 10.


What is the financial health of PURETECH HEALTH PLC - ADR (PRTC) stock?

The financial health rating of PURETECH HEALTH PLC - ADR (PRTC) is 5 / 10.